Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors
Risa Burr(Harvard University), Daniel A. Haber(Howard Hughes Medical Institute), Brian Chirn(Harvard University), Sara Y. Guay(Harvard University), Karsen Seeger(Harvard University), Raquel A. Jacobs(Broad Institute), Laxmi Parida(IBM (United States)), Justin Cha(Broad Institute), Taronish D. Dubash(Harvard University), Brian P. Danysh(Broad Institute), Martin Blohmer(Harvard University), Ira Gore(St. Vincent's Birmingham), Chaya Levovitz(IBM (United States)), Ignaty Leshchiner(Broad Institute), Kamila Naxerova(Harvard University), Kara Slowik(Broad Institute), Jochen K. Lennerz(Addgene), Filippo Utro(IBM (United States)), Shyamala Maheswaran(Massachusetts General Hospital), Mari Mino–Kenudson(Massachusetts General Hospital), Lecia V. Sequist(Harvard University), Christina L. Costantino(Harvard University), Tilak Sundaresan(Kaiser Permanente San Francisco Medical Center), Gad Getz(Broad Institute), Jaimie L. Barth(Harvard University), Kahn Rhrissorrakrai(IBM (United States))
Cited by 21
Related Papers
Integrative genomics viewer
|Nature Biotechnology|2011|16.5k
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k